The chemical class referred to as Kua-Uev Inhibitors comprises a group of compounds meticulously designed to selectively target the molecular entity known as Kua-Uev, where Uev stands for Ubiquitin-conjugating Enzyme Variant. Kua-Uev is a member of the ubiquitin-conjugating enzyme family, which plays a crucial role in the ubiquitin-proteasome system, a fundamental cellular mechanism for protein degradation and regulation. The ubiquitin-conjugating enzymes facilitate the transfer of ubiquitin molecules to target proteins, thereby marking them for degradation or modifying their activity. While the broader ubiquitin-conjugating enzyme family is well-established, the specific functions and regulatory mechanisms associated with Kua-Uev are subjects of active investigation within the field of molecular biology. Inhibitors within the Kua-Uev Inhibitors class are intricately engineered molecules with the primary goal of modulating the activity or function of Kua-Uev, thereby inducing an inhibitory effect. Researchers in this field adopt a multifaceted approach, integrating insights from structural biology, medicinal chemistry, and computational modeling to unravel the complex molecular interactions between the inhibitors and the target Kua-Uev.
Structurally, Kua-Uev Inhibitors are characterized by specific molecular features designed to facilitate selective binding to Kua-Uev. This selectivity is crucial to minimize unintended effects on other cellular components, ensuring a focused impact on the intended molecular target. The development of inhibitors within this chemical class involves a comprehensive exploration of structure-activity relationships, optimization of pharmacokinetic properties, and a deep understanding of the molecular mechanisms associated with Kua-Uev. As researchers delve deeper into the functional aspects of Kua-Uev Inhibitors, the knowledge generated contributes not only to deciphering the specific roles of Kua-Uev but also to advancing our broader comprehension of the ubiquitin-proteasome system, cellular protein regulation, and the intricate molecular events governing protein turnover within cells. The exploration of Kua-Uev Inhibitors stands as a significant avenue for expanding fundamental knowledge in molecular biology and cell physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and inhibits RNA synthesis, which could reduce the occurrence of readthrough transcription events like PEDS1-UBE2V1. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, potentially decreasing the transcription of readthrough transcripts such as PEDS1-UBE2V1. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
This compound is an adenosine analog that can inhibit transcription, possibly affecting PEDS1-UBE2V1 expression. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
As an inhibitor of transcription, triptolide may potentially reduce the expression of readthrough transcripts including PEDS1-UBE2V1. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin, an adenosine analog, can inhibit RNA polymerase and lead to the reduction of mRNA synthesis, possibly impacting PEDS1-UBE2V1 expression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases and can suppress RNA polymerase II-mediated transcription, which might reduce PEDS1-UBE2V1 expression. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide can inhibit translation and might indirectly affect the stability of readthrough transcripts like PEDS1-UBE2V1. | ||||||
Harringtonin | 26833-85-2 | sc-204771 sc-204771A sc-204771B sc-204771C sc-204771D | 5 mg 10 mg 25 mg 50 mg 100 mg | $250.00 $367.00 $548.00 $730.00 $980.00 | 30 | |
This compound inhibits protein synthesis at the initial elongation step, which could decrease the expression of proteins from readthrough transcripts. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, which could reduce PEDS1-UBE2V1 expression. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can modify gene expression and might have an indirect effect on the stability or expression of readthrough transcripts such as PEDS1-UBE2V1. | ||||||